Literature DB >> 22632365

Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor.

Seethalakshmi Iyer1, Rebecca Bahn.   

Abstract

Graves' ophthalmopathy is an inflammatory autoimmune disorder of the orbit. The close clinical and temporal relationships between Graves' hyperthyroidism and ophthalmopathy have long suggested that both conditions derive from a single systemic process and share the thyrotropin receptor as a common autoantigen. This receptor is expressed not only in thyroid follicular cells, but also in orbital fibroblasts with higher levels measured in orbital cells from ophthalmopathy patients than in cells from normal individuals. Recent studies from several laboratories have shown that thyrotropin receptor activation in orbital fibroblasts enhances hyaluronic acid synthesis and adipogenesis, both cellular functions that appear to be upregulated in the diseased orbit. The phosphoinositide 3-kinase/Akt signaling cascade, along with other effector pathways including adenylyl cyclase/cAMP, appears to mediate these processes. Future therapies for this condition may involve inhibition of thyrotropin receptor signaling in orbital fibroblasts.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22632365      PMCID: PMC3361679          DOI: 10.1016/j.beem.2011.10.003

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  68 in total

1.  T cells and fibroblasts in affected extraocular muscles in early and late thyroid associated ophthalmopathy.

Authors:  A Pappa; J M Lawson; V Calder; P Fells; S Lightman
Journal:  Br J Ophthalmol       Date:  2000-05       Impact factor: 4.638

2.  Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy.

Authors:  Terry J Smith; Laura Koumas; AnneMarie Gagnon; Andrea Bell; Gregory D Sempowski; Richard P Phipps; Alexander Sorisky
Journal:  J Clin Endocrinol Metab       Date:  2002-01       Impact factor: 5.958

3.  The human hyaluronan synthase genes: genomic structures, proximal promoters and polymorphic microsatellite markers.

Authors:  Jamie Monslow; John D Williams; Nadine Norton; Carol A Guy; Iain K Price; Sharon L Coleman; Nigel M Williams; Paul R Buckland; Andrew P Spicer; Nicholas Topley; Malcolm Davies; Timothy Bowen
Journal:  Int J Biochem Cell Biol       Date:  2003-08       Impact factor: 5.085

Review 4.  Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.

Authors:  Bellur S Prabhakar; Rebecca S Bahn; Terry J Smith
Journal:  Endocr Rev       Date:  2003-12       Impact factor: 19.871

5.  Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor.

Authors:  Terry J Smith; Neil Hoa
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

6.  Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo.

Authors:  K J Starkey; A Janezic; G Jones; N Jordan; G Baker; M Ludgate
Journal:  J Mol Endocrinol       Date:  2003-06       Impact factor: 5.098

7.  Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.

Authors:  D H Khoo; P H Eng; S C Ho; E S Tai; N G Morgenthaler; L L Seah; K S Fong; S P Chee; C T Choo; S E Aw
Journal:  Thyroid       Date:  2000-12       Impact factor: 6.568

Review 8.  Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor.

Authors:  Timothy E Adams; Neil M McKern; Colin W Ward
Journal:  Growth Factors       Date:  2004-06       Impact factor: 2.511

9.  Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.

Authors:  M N Gerding; J W van der Meer; M Broenink; O Bakker; W M Wiersinga; M F Prummel
Journal:  Clin Endocrinol (Oxf)       Date:  2000-03       Impact factor: 3.478

10.  The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim.

Authors:  Chun-Rong Chen; Pavel Pichurin; Yuji Nagayama; Francesco Latrofa; Basil Rapoport; Sandra M McLachlan
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

View more
  39 in total

Review 1.  Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yao Wang; Terry J Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

2.  Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy: a systematic review.

Authors:  S Seo; M Sánchez Robledo
Journal:  J Endocrinol Invest       Date:  2018-09-07       Impact factor: 4.256

Review 3.  Graves' orbitopathy: imperfect treatments for a rare disease.

Authors:  Luigi Bartalena
Journal:  Eur Thyroid J       Date:  2013-11-20

Review 4.  Thyroid eye disease: current and potential medical management.

Authors:  Jessica M Pouso-Diz; Jose M Abalo-Lojo; Francisco Gonzalez
Journal:  Int Ophthalmol       Date:  2020-01-09       Impact factor: 2.031

Review 5.  Clinical review: Clinical utility of TSH receptor antibodies.

Authors:  Giuseppe Barbesino; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

6.  [Update on endocrine orbitopathy].

Authors:  A Eckstein; U Berchner-Pfannschmidt; D Führer; J Esser
Journal:  Ophthalmologe       Date:  2013-11       Impact factor: 1.059

7.  Presence of thyroid-associated ophthalmopathy in Hashimoto's thyroiditis.

Authors:  Emrah Kan; Elif Kilic Kan; Gülcin Ecemis; Ramis Colak
Journal:  Int J Ophthalmol       Date:  2014-08-18       Impact factor: 1.779

Review 8.  Extrathyroidal manifestations of Graves' disease: a 2014 update.

Authors:  Luigi Bartalena; Vahab Fatourechi
Journal:  J Endocrinol Invest       Date:  2014-06-10       Impact factor: 4.256

9.  A modified ELISA accurately measures secretion of high molecular weight hyaluronan (HA) by Graves' disease orbital cells.

Authors:  Christine C Krieger; Marvin C Gershengorn
Journal:  Endocrinology       Date:  2013-12-03       Impact factor: 4.736

10.  Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy.

Authors:  Diego Strianese; Francesca Rossi
Journal:  Eye (Lond)       Date:  2019-01-04       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.